Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.
Sally W. Wade, MPH
Advertisement
Articles by Sally W. Wade, MPH
Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.
Advertisement
Latest Updated Articles
Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive DisorderPublished: July 23rd 2025 | Updated:
- Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis
Published: July 12th 2018 | Updated:
- Growth in Use of Lipid-lowering Therapies: Are We Targeting the Right Patients?
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Balancing Efficacy and Safety in BTKi Therapy
5
